Aclaris Therapeutics Inc
Company Profile
Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Contact
701 Lee Road
Suite 103
WaynePA19087
USAT: +1 484 324-7933
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73
Stocks News & Analysis
stocks
Wide moat ASX share beats earnings guidance
stocks
Cheap with attractive yield: Fair Value lifted for retail REIT after earnings
stocks
Cheap ASX share may have more room to run
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,443.70 | 17.90 | 0.19% |
| CAC 40 | 8,726.03 | 11.10 | 0.13% |
| DAX 40 | 26,323.88 | 4.43 | 0.02% |
| Dow JONES (US) | 53,975.98 | 60.95 | -0.11% |
| FTSE 100 | 10,862.50 | 38.59 | -0.35% |
| HKSE | 25,667.08 | 270.41 | -1.04% |
| NASDAQ | 26,605.36 | 85.26 | -0.32% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,860.66 | 27.58 | -0.20% |
| S&P 500 | 7,753.11 | 4.53 | -0.06% |
| S&P/ASX 200 | 9,250.60 | 13.80 | 0.15% |
| SSE Composite Index | 3,934.88 | 31.71 | -0.80% |